Acadia Pharma (ACAD): Offering Bridges Commercial Activities To 2019 - Piper Jaffray
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Acadia Pharmaceuticals (NASDAQ: ACAD) after ACADIA, yesterday, completed an offering of ~6M shares, raising $188M in net proceeds and pro-forma cash to ~$545M. The analyst believes this offering means the company’s clinical and commercial activities are well-funded into 1H19.
During this time, he expected ACADIA to make significant progress on the NUPLAZID commercial launch in the US and submit a marketing application in the EU. He believes the company can produce positive, potentially pivotal-stage data in AD agitation and advance NUPLAZID in a third possible indication such as schizophrenia or LBD.
Overall, he views the strengthened balance sheet as a positive in terms of supporting the marketing efforts needed for a successful PDP launch and funding clinical development to generate upside additional large-market neuro-psych indications. In advance of increased visibility on early traction in PDP, Phase II ADP data, and a Phase II/III ADA trial start by YE16,
No change to the price target of $44.00
Shares of Acadia Pharmaceuticals closed at $32.82 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- Jefferies Remains Sidelined on Capital One Financial (COF) Following EPS Beat
- Leerink Partners Cuts Price Target on Cynosure (CYNO) Following Solid 3Q
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesPiper Jaffray, Charles Duncan
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!